PARENTI, Carmela
 Distribuzione geografica
Continente #
NA - Nord America 10.643
EU - Europa 4.761
AS - Asia 4.483
SA - Sud America 701
AF - Africa 696
Continente sconosciuto - Info sul continente non disponibili 450
OC - Oceania 12
Totale 21.746
Nazione #
US - Stati Uniti d'America 10.256
SG - Singapore 2.241
RU - Federazione Russa 1.408
CN - Cina 1.206
IT - Italia 1.176
IE - Irlanda 610
BR - Brasile 567
UA - Ucraina 527
CI - Costa d'Avorio 375
VN - Vietnam 313
CA - Canada 276
FR - Francia 249
DE - Germania 211
KR - Corea 163
GB - Regno Unito 134
SE - Svezia 107
SN - Senegal 104
NG - Nigeria 103
IN - India 100
BD - Bangladesh 98
JP - Giappone 66
MX - Messico 53
ES - Italia 51
FI - Finlandia 48
PL - Polonia 47
HK - Hong Kong 44
NL - Olanda 40
ID - Indonesia 37
ZA - Sudafrica 37
AR - Argentina 35
IQ - Iraq 34
TR - Turchia 29
BE - Belgio 25
UZ - Uzbekistan 25
VE - Venezuela 25
CO - Colombia 21
AT - Austria 19
PK - Pakistan 19
CH - Svizzera 18
EC - Ecuador 17
KE - Kenya 17
AE - Emirati Arabi Uniti 16
CZ - Repubblica Ceca 16
CL - Cile 15
CR - Costa Rica 15
GR - Grecia 14
DZ - Algeria 12
JM - Giamaica 12
LB - Libano 12
AU - Australia 11
BJ - Benin 10
EG - Egitto 10
HU - Ungheria 10
LT - Lituania 10
MA - Marocco 10
TH - Thailandia 9
JO - Giordania 8
MY - Malesia 8
PE - Perù 8
PY - Paraguay 8
SA - Arabia Saudita 8
TN - Tunisia 7
AZ - Azerbaigian 6
ET - Etiopia 6
IL - Israele 6
IR - Iran 6
AL - Albania 5
EU - Europa 5
NP - Nepal 5
OM - Oman 5
PH - Filippine 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
BB - Barbados 4
BG - Bulgaria 4
HR - Croazia 4
NO - Norvegia 4
PT - Portogallo 4
RS - Serbia 4
BO - Bolivia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
AO - Angola 2
GT - Guatemala 2
LV - Lettonia 2
NI - Nicaragua 2
RO - Romania 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
BH - Bahrain 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
DM - Dominica 1
EE - Estonia 1
Totale 21.284
Città #
Dallas 1.710
Singapore 1.305
Santa Clara 1.043
Houston 1.030
Chandler 785
San Jose 682
Dublin 606
Moscow 575
Ashburn 555
Jacksonville 499
Chicago 470
Abidjan 375
Catania 348
Boardman 284
Nanjing 187
Beijing 181
Los Angeles 172
Cambridge 170
Lawrence 170
Andover 169
Hefei 169
Lauterbourg 165
Seoul 163
Toronto 161
Dakar 104
Council Bluffs 101
Ho Chi Minh City 97
Civitanova Marche 94
Wilmington 93
New York 85
San Mateo 84
Bremen 83
Des Moines 71
Buffalo 68
Hanoi 67
São Paulo 67
Nanchang 64
Tokyo 57
Columbus 52
The Dalles 51
Shenyang 50
Rome 46
Saint Petersburg 46
Abuja 45
Ottawa 43
Jiaxing 41
Lagos 40
Munich 40
Changsha 38
Hong Kong 38
Tianjin 37
Naples 36
Warsaw 36
Denver 35
Hebei 34
Atlanta 33
Brooklyn 32
Grafing 32
Montreal 29
Johannesburg 27
Orem 27
Brussels 24
Seattle 24
Phoenix 23
Jakarta 22
London 22
Amsterdam 20
Milan 20
Frankfurt am Main 19
Belo Horizonte 18
Chennai 18
Helsinki 18
Messina 18
Port Harcourt 18
Pune 18
Rio de Janeiro 18
Turku 18
Da Nang 17
Dong Ket 17
Falls Church 17
Baghdad 16
Mexico City 16
Poplar 16
San Giovanni la Punta 16
Washington 16
Jinan 15
Ningbo 15
Boston 14
Haiphong 14
Madrid 14
Norwalk 14
Palermo 14
San Francisco 14
Augusta 13
San José 13
Mascalucia 12
Paris 12
San Gregorio di Catania 12
Stockholm 12
Tashkent 12
Totale 14.646
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 461
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 413
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 353
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 322
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 233
Involvement of sigma 2 receptor on motor disorder 211
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 207
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 197
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 196
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 191
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 189
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 188
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 180
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 176
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 173
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 167
Connexins in the central nervous system: physiological traits and neuroprotective targets 164
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 163
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 160
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 160
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 157
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 155
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 153
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 153
Intercellular communication and ion channels in neuropathic pain chronicization 152
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 151
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 150
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 149
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 148
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 146
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 145
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 143
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 143
Apoptotic effects of (±) MRJF4 in prostate cancer cells 141
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 141
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 140
MOR/DOR targeting: an useful strategy in pain management 139
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 138
Dual-target ligands and pain: our experience 137
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 137
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 137
From plant to bench: natural products as source for analgesic drug development. 137
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 136
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 135
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 135
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 134
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 134
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 133
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 133
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 133
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 133
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 131
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 131
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 130
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 130
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 128
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 127
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 126
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 126
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 126
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 126
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 126
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 126
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 125
Sigma-2 receptor ligands QSAR model dataset 125
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 125
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 124
Central and peripheral involvement of endogenous opioid peptides in gastric protection in stressed rats 124
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 120
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 119
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 118
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 118
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 117
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 117
Multitarget opioid ligands in pain relief: New players in an old game 116
Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats. 116
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 114
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 112
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 112
Progress in the development of more effective and safer analgesics for pain management 110
In-vitro evaluation of a new benzomorphan-based ligand 109
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 109
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 108
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 108
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 108
Effect of arachidonic acid on pituitary immunoreactive B-endorphin levels in the rat 107
Idebenone: Novel strategies to improve its systemic and local efficacy 107
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 107
Wilms' tumor 1 (WT1) protein expression in human developing tissues 106
Evaluation of N-substitution in 6,7-benzomorphan compounds 106
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 106
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 105
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 104
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 103
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 103
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 102
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat 101
Pain management: new long-acting opioid ligands 101
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 99
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 98
Totale 14.544
Categoria #
all - tutte 68.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.082


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.203 0 175 15 38 207 16 184 55 120 23 55 315
2022/20232.384 193 127 46 289 208 374 8 433 501 45 98 62
2023/20241.258 82 217 76 60 68 286 48 76 2 33 217 93
2024/20254.039 67 736 210 236 865 476 196 185 242 318 241 267
2025/20268.705 518 333 1.883 444 1.298 1.606 974 171 456 526 303 193
2026/2027456 369 87 0 0 0 0 0 0 0 0 0 0
Totale 21.746